600056 中国医药
已收盘 01-23 15:00:00
资讯
新帖
简况
中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业
智通财经 · 01-22
中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业
国家医保局助推药械出海；减肥神药价格大跳水
21世纪经济报道 · 01-19
国家医保局助推药械出海；减肥神药价格大跳水
摩根士丹利邢自强：2040年将迎来中国医药界的DeepSeek时刻
睿见Economy · 01-15
摩根士丹利邢自强：2040年将迎来中国医药界的DeepSeek时刻
里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业
智通财经 · 01-14
里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业
中国医药(600056.SH)获准发行不超20亿元公司债券
智通财经 · 01-12
中国医药(600056.SH)获准发行不超20亿元公司债券
每周股票复盘：中国医药（600056）子公司获尼麦角林片注册证
证券之星 · 01-11
每周股票复盘：中国医药（600056）子公司获尼麦角林片注册证
中国医药（600056）披露子公司获得药品注册证书，1月8日股价上涨0.38%
证券之星 · 01-08
中国医药（600056）披露子公司获得药品注册证书，1月8日股价上涨0.38%
中国医药(600056.SH)子公司获得尼麦角林片药品注册证书
智通财经网 · 01-08
中国医药(600056.SH)子公司获得尼麦角林片药品注册证书
中国医药（600056）公司公告子公司收到《税务事项通知书》暨补缴税款相关事项，12月31日股价上涨0.29%
证券之星 · 2025-12-31
中国医药（600056）公司公告子公司收到《税务事项通知书》暨补缴税款相关事项，12月31日股价上涨0.29%
中国医药最新公告：子公司天方药业的克拉霉素片通过仿制药一致性评价
证券之星 · 2025-12-31
中国医药最新公告：子公司天方药业的克拉霉素片通过仿制药一致性评价
中国医药最新公告：子公司需补缴税款及滞纳金约6521.78万元
证券之星 · 2025-12-31
中国医药最新公告：子公司需补缴税款及滞纳金约6521.78万元
中国医药：拟5.25亿元购买则正医药70%股权
新京报 · 2025-12-30
中国医药：拟5.25亿元购买则正医药70%股权
每周股票复盘：中国医药（600056）子公司获瑞舒伐他汀依折麦布片注册证
证券之星 · 2025-12-28
每周股票复盘：中国医药（600056）子公司获瑞舒伐他汀依折麦布片注册证
中国医药（600056）披露子公司获得药品注册批件，12月24日股价上涨0.19%
证券之星 · 2025-12-24
中国医药（600056）披露子公司获得药品注册批件，12月24日股价上涨0.19%
中国医药(600056.SH)子公司获瑞舒伐他汀依折麦布片(I)药品注册批件
智通财经 · 2025-12-24
中国医药(600056.SH)子公司获瑞舒伐他汀依折麦布片(I)药品注册批件
交银国际：中国医药1-8批国采接续规则或温和 短期催化剂充足
智通财经 · 2025-12-05
交银国际：中国医药1-8批国采接续规则或温和 短期催化剂充足
联邦制药荣登2025中国医药上市公司ESG竞争力TOP20，获最具竞争力20强
联邦制药 · 2025-11-26
联邦制药荣登2025中国医药上市公司ESG竞争力TOP20，获最具竞争力20强
中国医药修订内部审计制度并制定董事会议案管理办法
中金财经 · 2025-11-25
中国医药修订内部审计制度并制定董事会议案管理办法
中国医药(600056.SH)：注射用更昔洛韦通过仿制药一致性评价
智通财经网 · 2025-11-21
中国医药(600056.SH)：注射用更昔洛韦通过仿制药一致性评价
中国医药：截至2025年9月30日，公司股东总数为139689户
证券日报 · 2025-11-20
中国医药：截至2025年9月30日，公司股东总数为139689户
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药商业、医疗器械、国际贸易。公司入选药智网“2025中国化药研发实力排行榜TOP100”第50位；入选第七届CMC-CHINA中国制药工业博览会“2025中国制药工业TOP101”第87位。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":10.74,"timestamp":1769151602000,"preClose":10.62,"halted":0,"volume":24540653,"delay":0,"changeRate":0.0113,"floatShares":1495000000,"shares":1496000000,"eps":0.3631,"marketStatus":"已收盘","change":0.12,"latestTime":"01-23 15:00:00","open":10.71,"high":10.89,"low":10.7,"amount":264000000,"amplitude":0.0179,"askPrice":10.75,"askSize":1548,"bidPrice":10.74,"bidSize":84,"shortable":0,"etf":0,"ttmEps":0.3631,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769391000000},"marketStatusCode":5,"adr":0,"adjPreClose":10.62,"symbolType":"stock","openAndCloseTimeList":[[1769131800000,1769139000000],[1769144400000,1769151600000]],"highLimit":11.68,"lowLimit":9.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.36,"roa":"--","peRate":29.578628,"roe":"3.72%","epsLYR":0.358,"committee":0.098417,"marketValue":16066000000,"turnoverRate":0.0164,"status":0,"floatMarketCap":16060000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2605546621","title":"中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2605546621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605546621?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:30","pubTimestamp":1769070647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。整体看，中国医药产业正站在全球化价值重估的起点，2026年将成为验证转型成效的关键节点。中国药企呈现全球化提速的格局。中国CXO企业凭借ADC、双抗、GLP-1等领域的一站式服务平台能力，完成从“中间供应商”到“全球创新赋能者”的跃升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601066","BK0010","BK0082","159992","BK0276","01477","600056","BK0175","BK0250","BK1191","BK1574","BK0028","BK0188","06978","BK0185","BK1161"],"gpt_icon":0},{"id":"2604083739","title":"国家医保局助推药械出海；减肥神药价格大跳水","url":"https://stock-news.laohu8.com/highlight/detail?id=2604083739","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604083739?lang=zh_cn&edition=full","pubTime":"2026-01-19 08:02","pubTimestamp":1768780979,"startTime":"0","endTime":"0","summary":"国家医保局助推药械出海；减肥神药价格大跳水","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601193622762816.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601193622762816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0077","BK0239","BK0188","688580","BK0185","600056","002317","BK0250","BK0082","BK0028","BK0251","BK0010","BK0175"],"gpt_icon":0},{"id":"2603168601","title":"摩根士丹利邢自强：2040年将迎来中国医药界的DeepSeek时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168601","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603168601?lang=zh_cn&edition=full","pubTime":"2026-01-15 19:26","pubTimestamp":1768476360,"startTime":"0","endTime":"0","summary":"摩根士丹利中国首席经济学家邢自强指出，中国在科技创新领域正展现“星辰大海”式突破，三大核心优势：产业链集群、理工科人才红利、超大市场规模，这些难以被其他经济体复制。 他还指出，中国智能驾驶普及率全球领先、生物制药行业迎来爆发式增长，“我们测算，到了2040年，基本上美国FDA批准的新的创新药里，三分之一以上来自于中国，这也是中国医药界的DeepSeek时刻。”","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-01-15/doc-inhhkwct6264467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600056","MS"],"gpt_icon":0},{"id":"2603664448","title":"里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603664448?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:20","pubTimestamp":1768371626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，展望2026年，相信对中国医疗板块而言，盈利交付将比估值扩张更为重要，料药明康德 有望跑赢同业。该行将药明康德列为中国CRO/CDMO行业的首选。该行维持药明康德“跑赢大市”评级及目标价143.4港元。相较同行，药明康德具备更强的盈利增长可见性：其2025年前三季度订单储备同比增长41%，远高于全球平均约14%，即使在地缘政治风险持续的背景下仍保持强劲增势。该行预计2026年药明康德的订单增速将继续领先全球同行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245094.SGD","BK0010","LU1046422090.SGD","LU1934453819.USD","BK0185","LU0708995583.HKD","02359","LU0320764599.SGD","LU1997244956.HKD","BK0028","BK0250","LU0052750758.USD","LU2495084118.USD","LU0456842615.SGD","CDMO","LU1997245177.USD","BK4139","BK0175","BK0188","BK1141","603259","BK1583","BK0082","LU2125910500.SGD","LU2045819591.USD","600056","BK0216","LU2328871848.SGD","LU2242644610.SGD","BK1576","LU2488822045.USD","LU1808992512.USD","LU1979443071.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2602851514","title":"中国医药(600056.SH)获准发行不超20亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602851514?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:18","pubTimestamp":1768213114,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司收到中国证券监督管理委员会《关于同意中国医药健康产业股份有限公司向专业投资者公开发行公司债券注册的批复》(证监许可〔2026〕21号)。据此批复，公司可以向专业投资者公开发行面值总额不超过20亿元公司债券。此批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600056","BK0188","BK0175","BK0082","BK0250","BK0185","BK0028","BK0010"],"gpt_icon":0},{"id":"2602535349","title":"每周股票复盘：中国医药（600056）子公司获尼麦角林片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535349","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535349?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:33","pubTimestamp":1768069987,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，中国医药报收于10.82元，较上周的10.33元上涨4.74%。本周，中国医药1月9日盘中最高价报10.84元。1月5日盘中最低价报10.3元。中国医药当前最新总市值161.85亿元，在医药商业板块市值排名6/32，在两市A股市值排名1284/5182。截至目前，国内已有包括三洋药业在内的十余家企业取得该药品批件。2024年该药品在中国三大终端六大市场的销售额约为34,972万元。此次获批有助于丰富公司产品线，完善神经系统用药领域布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","BK0188","BK0185","BK0082","600056","BK0250","BK0010"],"gpt_icon":0},{"id":"2601986733","title":"中国医药（600056）披露子公司获得药品注册证书，1月8日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601986733","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601986733?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:36","pubTimestamp":1767882979,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，中国医药报收于10.54元，较前一交易日上涨0.38%，最新总市值为157.67亿元。公司近日发布公告称，其全资子公司海南通用三洋药业有限公司获得国家药品监督管理局核准签发的尼麦角林片药品注册证书，药品注册分类为化学药品3类。截至目前，国内已有包括三洋药业在内的十余家企业取得该药品批件。2024年该药品在中国三大终端六大市场的销售额约为34,972万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0028","BK0082","BK0185","BK0010","BK0188","BK0175","BK0250"],"gpt_icon":0},{"id":"2601351496","title":"中国医药(600056.SH)子公司获得尼麦角林片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351496","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351496?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:36","pubTimestamp":1767861387,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司海南通用三洋药业有限公司(简称“三洋药业”)收到国家药品监督管理局核准签发的尼麦角林片《药品注册证书》。尼麦角林片主要用于改善由于脑梗塞后遗症引起的意欲低下;也适用于血管性痴呆，尤其在早期治疗时对认知、记忆等有改善，并能减轻疾病严重程度。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国医药(600056.SH)子公司获得尼麦角林片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0082","BK0010","BK0028","BK0250","600056","BK0185","BK0175","BK0188"],"gpt_icon":0},{"id":"2595777642","title":"中国医药（600056）公司公告子公司收到《税务事项通知书》暨补缴税款相关事项，12月31日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777642","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777642?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:24","pubTimestamp":1767191063,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，中国医药报收于10.33元，较前一交易日上涨0.29%，最新总市值为154.52亿元。该股当日开盘10.32元，最高10.37元，最低10.27元，成交额达7810.71万元，换手率为0.51%。近日，中国医药发布公告称，公司全资子公司三洋药业和康力药业分别收到税务部门通知，需补缴税款及滞纳金。三洋药业补缴税款2,148.62万元，滞纳金约1,074.29万元；康力药业补缴税款2,128.26万元，滞纳金约1,170.61万元。合计补缴金额约6,521.78万元，不涉及行政处罚。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0175","600056","BK0028","BK0185","BK0082","BK0188","BK0010"],"gpt_icon":0},{"id":"2595777822","title":"中国医药最新公告：子公司天方药业的克拉霉素片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777822","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777822?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:11","pubTimestamp":1767175864,"startTime":"0","endTime":"0","summary":"中国医药公告称，公司下属全资子公司天方药业收到国家药监局核准签发的克拉霉素片《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。截至公告披露日，除天方药业外，国内已有10多家企业通过或视同通过该药品的一致性评价。该药品2024年国内公立医院及公立基层医疗终端销售额约为4.07亿元。天方药业的克拉霉素片通过一致性评价，有助于提升该药品的市场竞争力，但未来可能存在销售不达预期等风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600056","BK0188","BK0185","BK0175","BK0250","BK0028","BK0082"],"gpt_icon":0},{"id":"2595778243","title":"中国医药最新公告：子公司需补缴税款及滞纳金约6521.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778243?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:09","pubTimestamp":1767175784,"startTime":"0","endTime":"0","summary":"中国医药(600056.SH)公告称，公司下属全资子公司海南通用三洋药业有限公司和海南康力药业有限公司分别收到《税务事项通知书》，需补缴税款及滞纳金约6521.78万元。补缴税款和滞纳金将计入公司2025年当期损益，预计影响公司2025年度净利润6521.78万元。本次补缴税款事项不会影响公司的正常经营。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0010","BK0175","600056","BK0082","BK0185","BK0188","BK0028"],"gpt_icon":0},{"id":"2595151793","title":"中国医药：拟5.25亿元购买则正医药70%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2595151793","media":"新京报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595151793?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:23","pubTimestamp":1767086580,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 中国医药公告，公司与13名交易对方签署《关于上海则正医药科技股份有限公司之购买股份协议》，以现金出资5.25亿元人民币购买交易对方合计所持上海则正医药科技股份有限公司70%股权。则正医药是一家以改良型新药、复杂制剂为特色的医药研发企业，提供药品研究、临床试验、注册申报的全流程研发服务。本次交易旨在提升中国医药在医药研发创新领域的综合实力，弥补当前研发体系短板，打通研发到生产的全产业链。交易已获董事会审议通过，无需提交股东会审议。交易完成后，则正医药将成为中国医药下属控股子公司。","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/30/5670113380954876296.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/30/5670113380954876296.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767084643129820.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1767084643129820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK1574","BK0082","BK1161","09939","BK0175","159938","BK0188","BK1515","BK0010","600056","BK0028","BK0250","BK0185"],"gpt_icon":0},{"id":"2594072244","title":"每周股票复盘：中国医药（600056）子公司获瑞舒伐他汀依折麦布片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2594072244","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594072244?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:25","pubTimestamp":1766863512,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，中国医药报收于10.47元，较上周的10.63元下跌1.51%。本周，中国医药12月22日盘中最高价报10.63元。本周关注点公司公告汇总：子公司天方药业获瑞舒伐他汀依折麦布片药品注册证书公司公告汇总：瑞舒伐他汀依折麦布片2025年前三季度中国三大终端销售额达2,353万元公司公告汇总：该产品累计研发投入约2,439万元公司公告汇总中国医药全资子公司天方药业近日获得国家药监局核准签发的瑞舒伐他汀依折麦布片药品注册证书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0188","BK0082","BK0250","BK0010","BK0175","600056"],"gpt_icon":0},{"id":"2593408543","title":"中国医药（600056）披露子公司获得药品注册批件，12月24日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593408543","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593408543?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:46","pubTimestamp":1766587590,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，中国医药报收于10.48元，较前一交易日上涨0.19%，最新总市值为156.77亿元。该股当日开盘10.41元，最高10.5元，最低10.41元，成交额达6696.63万元，换手率为0.43%。公司近日发布公告称，其全资子公司天方药业获得国家药监局核准签发的瑞舒伐他汀依折麦布片药品注册证书。截至目前，国内已有包括天方药业在内的4家企业获批该药品批件。2024年该药品在中国三大终端销售额约146万元，2025年前三季度约为2,353万元。此次获批有助于丰富公司产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400041440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0010","BK0250","BK0028","BK0188","BK0082","BK0185","600056"],"gpt_icon":0},{"id":"2593357478","title":"中国医药(600056.SH)子公司获瑞舒伐他汀依折麦布片(I)药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2593357478","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593357478?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:44","pubTimestamp":1766565843,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司天方药业有限公司(简称“天方药业”)收到国家药品监督管理局核准签发的瑞舒伐他汀依折麦布片(I)《药品注册证书》。瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症(HoFH)。依折麦布与瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国医药(600056.SH)子公司获瑞舒伐他汀依折麦布片(I)药品注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0175","BK0250","BK0028","600056","BK0188","BK0185","BK0010"],"gpt_icon":0},{"id":"2589852755","title":"交银国际：中国医药1-8批国采接续规则或温和 短期催化剂充足","url":"https://stock-news.laohu8.com/highlight/detail?id=2589852755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589852755?lang=zh_cn&edition=full","pubTime":"2025-12-05 10:18","pubTimestamp":1764901122,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，本周恒生医疗保健指数涨0.5%，跑输大市。其中，生物药、处方药及器械板块表现较优于其他板块。本周内资偏向防御，倾向获利了结，主要加仓内生增长稳定的传统及低估创新药厂。而外资则较积极，聚焦创新主线中的龙头及产业链上游，包括创新药及CXO标的。1-8批集采接续采购规则转变为询价模式，交银国际认为此规则下整体降价幅度或有限，对港股处方药厂的影响或小于预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","06996","BK0028","BK0082","BK1583","BK0185","LU2488822045.USD","SG9999014674.SGD","BK1161","01530","02268","BK0188","02096","BK1588","03329","BK1141","BK1574","BK1147","BK1587","BK1191","600056","BK1593","BK0175","BK0250","00013","HK0000165453.HKD"],"gpt_icon":0},{"id":"2586257032","title":"联邦制药荣登2025中国医药上市公司ESG竞争力TOP20，获最具竞争力20强","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257032","media":"联邦制药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586257032?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:34","pubTimestamp":1764164040,"startTime":"0","endTime":"0","summary":"11月26日，在北京举办的首届中国医药上市公司价值管理峰会颁奖典礼上，联邦制药凭借在ESG透明度、ESG治理及重要性议题管理评价方面的卓越表现，荣登“2025中国医药上市公司ESG竞争力TOP20（ ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251126/c672765833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0250","159717","BK0175","BK0188","BK0082","BK0028","BK0010","BK0185","600056"],"gpt_icon":0},{"id":"2586443654","title":"中国医药修订内部审计制度并制定董事会议案管理办法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586443654","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586443654?lang=zh_cn&edition=full","pubTime":"2025-11-25 11:33","pubTimestamp":1764041591,"startTime":"0","endTime":"0","summary":"中访网数据 中国医药健康产业股份有限公司于2025年11月24日召开了第九届董事会第33次会议。本次会议审议并通过了《关于修订的议案》和《关于制定的议案》两项重要制度。会议由公司董事长兼总经理杨光先生主持，应出席董事8名，实际出席8名，会议的召集和召开程序符合《公司法》及《公司章程》的规定。这两项制度的修订与制定，旨在进一步完善公司的治理结构和内部控制体系，规范内部审计工作流程，并明确董事会议案的提交与管理规范，以提升公司决策效率和治理水平，保障公司合规稳健运营。相关制度全文已按规定进行披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251125/31821637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600056","BK0028","BK0185","BK0250","BK0188","BK0010","BK0175","BK0082"],"gpt_icon":0},{"id":"2585144151","title":"中国医药(600056.SH)：注射用更昔洛韦通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2585144151","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585144151?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:47","pubTimestamp":1763722024,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司海南通用康力制药有限公司(以下简称“康力药业”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发的两份注射用更昔洛韦(以下简称“该药品”)《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。注射用更昔洛韦主要适用于治疗危及生命或视觉的免疫缺陷患者的巨细胞病毒感染，以及预防器官移植病人的巨细胞病毒感染。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0185","600056","BK0082","BK0010","BK0188","BK0250","BK0028","BK0175"],"gpt_icon":0},{"id":"2584137949","title":"中国医药：截至2025年9月30日，公司股东总数为139689户","url":"https://stock-news.laohu8.com/highlight/detail?id=2584137949","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584137949?lang=zh_cn&edition=full","pubTime":"2025-11-20 21:42","pubTimestamp":1763646120,"startTime":"0","endTime":"0","summary":"证券日报网讯中国医药11月20日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东总数为139，689户。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infyafyw0744239.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infyafyw0744239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600056","BK0188","BK0175","BK0082","BK0250","BK0185","BK0028","BK0010"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769377050565,"stockEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":0.0248},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0085},{"period":"1year","weight":0.0213},{"period":"ytd","weight":0.0397}],"compareEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0495},{"period":"3month","weight":0.047},{"period":"6month","weight":0.151},{"period":"1year","weight":0.2805},{"period":"ytd","weight":0.0422}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"139689人(较上一季度增加0.69%)","perCapita":"10704股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药商业、医疗器械、国际贸易。公司入选药智网“2025中国化药研发实力排行榜TOP100”第50位；入选第七届CMC-CHINA中国制药工业博览会“2025中国制药工业TOP101”第87位。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}